P. Livingston

发表

GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3.

W. Zollinger, G. Lowell, P. Livingston, 1993, Vaccine.

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

J. Wolchok, M. Perales, A. Houghton, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.

J. Menell, A. Houghton, P. Chapman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

P O Livingston, L. Old, E. Stockert, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

P. Livingston, D. Gin, J. Gardner, 2011, Expert review of vaccines.

Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans

G. Ragupathi, P. Livingston, 1997, Cancer Immunology, Immunotherapy.

Carbohydrate Vaccines Against Cancer

P. Livingston, G. Ragupathi, 2007 .

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2007, Clinical Cancer Research.

Cancer Vaccines Targeting Carbohydrate Antigens

P. Livingston, G. Ragupathi, 2006, Human vaccines.

Antibody inducing polyvalent cancer vaccines.

P. Livingston, G. Ragupathi, J. Gathuru, 2005, Cancer treatment and research.

Antibody-Inducing Cancer Vaccines Against Cell-Surface Carbohydrate Antigens

P. Livingston, G. Ragupathi, J. Gathuru, 2004 .

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.

W. Bornmann, S. Danishefsky, S. Yi, 2002, Vaccine.

Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

H. Scher, W. Bornmann, A. Zatorski, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.

Jonathan J. Lewis, P. Chapman, K. Panageas, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.

P. Chapman, K. Panageas, Philip S. Livingston, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vaccination with a Bivalent GM 2 and GD 2 Ganglioside Conjugate Vaccine : A Trial Comparing Doses of GD 2-Keyhole Limpet Hemocyanin 1

Jonathan J. Lewis, P. Chapman, K. Panageas, 2000 .

Immunogenicity of a Fucosyl-GM 1-Keyhole Limpet Hemocyanin Conjugate Vaccine in Patients with Small Cell Lung Cancer 1

M. Kris, V. Miller, C. Musselli, 1999 .

Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.

M. Kris, V. Miller, C. Musselli, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunogenicity of synthetic conjugates of Lewisy oligosaccharide with proteins in mice: towards the design of anticancer vaccines

S. Danishefsky, K. Lloyd, G. Ragupathi, 1998, Cancer Immunology, Immunotherapy.

Augmenting the immunogenicity of carbohydrate tumor antigens.

P. Livingston, 1995, Seminars in cancer biology.

Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma

L. Old, H. Oettgen, S. Ren, 1995, International journal of cancer.

GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

H. Oettgen, B. Longenecker, S. Adluri, 1995, Cancer research.

Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

Philip S. Livingston, P. Livingston, 1995, Immunological reviews.

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

C. Kensil, Philip S. Livingston, D. Marciani, 1994, Vaccine.

Ganglioside conjugate vaccines

Philip S. Livingston, P. Livingston, F. Helling, 1994, Molecular and chemical neuropathology.

Approaches to Augmenting the IgG Antibody Response to Melanoma Ganglioside Vaccines

P. Livingston, PHILIP O. LIVINGSTON, 1993, Annals of the New York Academy of Sciences.

Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma

L. Old, H. Oettgen, Philip S. Livingston, 1991, International journal of cancer.

Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse.

L. Old, H. Oettgen, G. Ritter, 1990, Immunobiology.

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma

J. Wolchok, M. Perales, A. Houghton, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

K. Sepkowitz, J. Wolchok, P. Chapman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ganglioside expression on human malignant melanoma assessed by quantitative immune thin‐layer chromatography

Philip S. Livingston, K. Lloyd, P. Livingston, 1993, International journal of cancer.

Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

G. Ragupathi, P. Livingston, R. Sawada, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical Human Monoclonal Antibodies to Sialyl-Lewisa ( CA 19 . 9 ) with Potent CDC , ADCC , and Antitumor Activity

G. Ragupathi, P. Livingston, R. Sawada, 2011 .

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

A. Houghton, P. Chapman, Philip S. Livingston, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of minimal tumor burden on antibody response to vaccination

N. Cheung, K. Panageas, P. Livingston, 2011, Cancer Immunology, Immunotherapy.

Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin

M. Kris, V. Miller, L. Krug, 2004, Clinical Cancer Research.

Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21

C. Hudis, L. Norton, A. Houghton, 2007, Clinical Cancer Research.

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Derek S. Tan, P. Livingston, D. Gin, 2014, Bioorganic & medicinal chemistry.

Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes.

M. Adams, P. Livingston, D. Gin, 2012, Journal of the American Chemical Society.

Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale

K. Lloyd, Shengle Zhang, P. Livingston, 1997, Cancer Immunology, Immunotherapy.

Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens

P. Livingston, 1992, Current Biology.

Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.

O. Ouerfelli, S. Danishefsky, Y. Cho, 2006, Journal of the American Chemical Society.

Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.

S. Danishefsky, G. Ragupathi, P. Livingston, 2009, Journal of the American Chemical Society.

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

L. Norton, M. Moynahan, A. Houghton, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Constructing an adenocarcinoma vaccine: Immunization of mice with synthetic KH‐1 nonasaccharide stimulates anti‐KH‐1 and anti‐Ley antibodies

S. Danishefsky, Philip S. Livingston, L. Williams, 2002, International journal of cancer.

Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin

M. Kris, V. Miller, L. Krug, 2004, Clinical Cancer Research.

Vaccines for melanoma: translating basic immunology into new therapies.

J. Wolchok, P. Livingston, PO Livingston, 2001, The Lancet. Oncology.

Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.

N. Kemeny, L. Old, H. Oettgen, 1992, Cancer research.

Immunization of ovarian cancer patients with a synthetic Lewisy‐protein conjugate vaccine: A phase 1 trial

M. Peyton, S. Soignet, P. Sabbatini, 2000, International journal of cancer.

Antibodies against GD 2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases 1

N. Cheung, Shengle Zhang, G. Ragupathi, 2006 .

Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.

N. Cheung, H. Zhang, G. Ragupathi, 1998, Cancer research.

Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity1

C. Musselli, K. Lloyd, P. Livingston, 2005, The Journal of Immunology.

On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines

S. Danishefsky, L. Williams, G. Ragupathi, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

H. Scher, S. Kuduk, K. Olkiewicz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”

M. Morris, H. Scher, D. Solit, 2007, Cancer Immunology, Immunotherapy.

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers

W. Bornmann, H. Clausen, S. Danishefsky, 2003, Cancer Immunology, Immunotherapy.

A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates

L. BenMohamed, C. Leclerc, S. Bay, 2004, Cancer Research.

Synthetic and Immunological Studies on Clustered Modes of Mucin-Related Tn and TF O-Linked Antigens: The Preparation of a Glycopeptide-Based Vaccine for Clinical Trials against Prostate Cancer†

S. Kuduk, Xiao-tao Chen, S. Danishefsky, 1998 .

Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.

K. Lloyd, S. Adluri, L. Graeber, 1996, Cancer research.

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells

M. Reddish, B. Longenecker, Philip S. Livingston, 1999, Cancer Immunology, Immunotherapy.

Cancer Therapy : Preclinical Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-InducedComplement Activation Is Associatedwith Activation of the PI 3 K / AKT Survival Pathway

K. Panageas, G. Ragupathi, P. Livingston, 2013 .

Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation Is Associated with Activation of the PI3K/AKT Survival Pathway

K. Panageas, G. Ragupathi, P. Livingston, 2013, Clinical Cancer Research.

Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology

Jason S. Lewis, S. Carlin, Nerissa T Viola-Villegas, 2013, The Journal of Nuclear Medicine.

Monoclonal antibodies and immobilized antibodies

C. A. White, R. Krauss, M. Melamed, 1987 .

Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21

Philip S. Livingston, Shengle Zhang, T. Gilewski, 1999, British Journal of Cancer.

Ganglioside vaccines with emphasis on GM2.

P. Livingston, 1998, Seminars in oncology.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.

C. Cordon-Cardo, Philip S. Livingston, Shengle Zhang, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fully S ynthetic C arbohydrate-Bas ed V accines i n B iochemically Relapsed P rostate C ancer: C linical T rial R esults With - N -Acetylgalactosa mine- O -Serine/Threonin e Conjugate V accine

H. Scher, S. Kuduk, K. Olkiewicz, 2003 .

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.

A. Zelenetz, D. Scheinberg, D. Agus, 2002, Blood.

Vaccines and other adjuvant therapies for melanoma.

J. Wolchok, A. Houghton, P. Livingston, 1998, Hematology/oncology clinics of North America.

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn

D. Kahne, H. Clausen, S. Danishefsky, 2005, Cancer Immunology, Immunotherapy.

A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.

E. Gilboa, H. Oettgen, S. Yang, 1992, Human gene therapy.

Active Specific Immunotherapy in the Treatment of Patients with Cancer

P. Livingston, 1991, Immunology and Allergy Clinics of North America.

Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

L. Old, E. Stockert, H. Oettgen, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

G. Ragupathi, P. Livingston, S. Cappello, 2000, Vaccine.

Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.

Kazuro Furukawa, L. Old, H. Oettgen, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Autoimmune and Antitumor Consequences of Antibodies Against Antigens Shared by Normal and Malignant Tissues

C. Musselli, G. Ragupathi, P. Livingston, 2000, Journal of Clinical Immunology.

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

C. Musselli, G. Ragupathi, P. Livingston, 1999, Vaccine.

Anti‐melanoma effects of R24, a monoclonal antibody against GD3 ganglioside

A. Houghton, P. Chapman, Philip S. Livingston, 1997, Melanoma research.

Immunization with N-propionyl polysialic acid–KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci

M. Kris, R. Shen, L. Krug, 2011, Cancer Immunology, Immunotherapy.

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.

G. T. Budd, Robin L. Jones, L. Qin, 2022, European journal of cancer.

Vaccination with CD 20 peptides induces a biologically active , specific immune response in mice

A. Zelenetz, D. Scheinberg, D. Agus, 2002 .

Saponin QS-21 adjuvants in cancer vaccines

P. Livingston, D. Gin, J. Gardner, 2011 .

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients

S. Itzkowitz, K. Lloyd, Shengle Zhang, 1995, Cancer Immunology, Immunotherapy.

Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.

M. Reddish, B. Longenecker, S. Itzkowitz, 1995, Cancer research.

Development of a minimal saponin vaccine adjuvant based on QS-21

Derek S. Tan, Jason S. Lewis, N. Pillarsetty, 2014, Nature chemistry.

A second generation synthesis of the MBr1 (globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages.

A. Zatorski, S. Danishefsky, G. Ragupathi, 2000, Chemistry.

A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle.

H. Scher, W. Bornmann, S. Slovin, 1999, Angewandte Chemie.

TOTAL SYNTHESIS OF A HUMAN BREAST TUMOR ASSOCIATED ANTIGEN

J. Randolph, S. Danishefsky, S. Zhang, 1995 .

Temozolomide Plus Thal idomide in Pat ients With Advanced Melanoma : Resul ts of a Dose-Finding Tria l

J. Menell, A. Houghton, P. Chapman, 2002 .

Chemical and genetic assessment of variability in commercial Radix Astragali (Astragalus spp.) by ion trap LC-MS and nuclear ribosomal DNA barcoding sequence analyses.

E. Kennelly, P. Leung, C. Lau, 2011, Journal of agricultural and food chemistry.

Design and synthesis of potent Quillaja saponin vaccine adjuvants.

M. Adams, P. Livingston, D. Gin, 2010, Journal of the American Chemical Society.

HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis.

M. Pollack, P. Livingston, 2008, Tissue antigens.

A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity.

L. Old, H. Oettgen, K. Lloyd, 1986, Cancer research.

The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines

L. Old, H. Oettgen, C. Pinsky, 1985, Cancer.

Carbohydrate-Based Vaccines

G. Ragupathi, P. Livingston, 2002 .

Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides

K. Lloyd, Shengle Zhang, P. Livingston, 1995, Cancer Immunology, Immunotherapy.

Defining the Molecular Recognition of MBr1 (Human Breast Cancer) Antigen by the MBr1 Antibody through Probe Structures Prepared by Total Synthesis

S. Danishefsky, Shengle Zhang, P. Livingston, 1995 .

Strategy in Oligosaccharide Synthesis: An Application to a Concise Total Synthesis of the KH-1(adenocarcinoma) Antigen

A. Zatorski, S. Danishefsky, G. Ragupathi, 1998 .

Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.

R. Kerns, T. Coleman, P. Livingston, 2005, Vaccine.

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

M. Kris, L. Krug, T. Brezicka, 2005, Cancer Immunology, Immunotherapy.

Keyhole limpet hemocyanin conjugate vaccines against cancer: The Memorial Sloan Kettering experience

C. Musselli, G. Ragupathi, P. Livingston, 2001, Journal of Cancer Research and Clinical Oncology.

Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma

J. Wolchok, M. Fleisher, P. Chapman, 2003, Melanoma research.

Synthesis of the melanoma-associated ganglioside 9-O-acetyl GD3 through regioselective enzymatic acetylation of GD3 using subtilisin

Chi‐Huey Wong, P. Livingston, S. Takayama, 1996 .

Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse

G. Ritter, P. Livingston, M. Calves, 2004, Cancer Immunology, Immunotherapy.

GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.

P O Livingston, H. Oettgen, S. Ren, 1994, Cancer research.

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

G. Wong, Philip S. Livingston, G. Wong, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells

A. Houghton, L. Old, A. Albino, 1982, International journal of cancer.

Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.

W. Enker, P. Livingston, G. Schiffman, 1987, Journal of biological response modifiers.

Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.

P. Livingston, M. Calves, E. Natoli, 1987, Journal of immunology.

Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.

V. Reuter, H. Scher, P. Livingston, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1

K. Panageas, C. Musselli, Philip S. Livingston, 2002, International journal of cancer.

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

M. Adams, K. Deng, G. Ragupathi, 2010, Vaccine.

Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3.

A. Slominski, R. Yu, T. Ariga, 1993, Journal of lipid research.

Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.

W. Bornmann, S. Danishefsky, G. Ragupathi, 2005, The Journal of organic chemistry.

Immunization of Mice with a Fully Synthetic Globo H Antigen Results in Antibodies against Human Cancer Cells: A Combined Chemical—Immunological Approach to the Fashioning of an Anticancer Vaccine

S. Danishefsky, K. Lloyd, Shengle Zhang, 1997 .

Defining the Molecular Recognition of Globo H (Human Breast Cancer) Antigen Through Probe Structures Prepared by Total Synthesis.

S. Danishefsky, P. Livingston, T. Park, 1996 .

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer

H. Scher, S. Slovin, S. Danishefsky, 2005, Cancer Immunology, Immunotherapy.

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

J. Wolchok, P. Chapman, W. Hwu, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

M. Adams, K. Deng, P. Livingston, 2008, Angewandte Chemie.

T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

Jonathan J. Lewis, A. Houghton, P. Chapman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.

A. Deleo, H. Oettgen, P. Livingston, 1983, Journal of immunology.

Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.

P O Livingston, P. Srivastava, L. Old, 1989, Cancer research.

The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.

E. Kennelly, P. Leung, C. Lau, 2011, Planta medica.

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.

H. Scher, N. Rosen, J. Mendelsohn, 1996, Seminars in oncology.

Brief communication: HLA antigen frequencies in renal cell carcinoma.

M. Pollack, P. Livingston, 1984, Human immunology.

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

J. Menell, J. Wolchok, A. Houghton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide plus thalidomide in patients with brain metastases from melanoma

J. Menell, J. Wolchok, E. Lis, 2005, Cancer.

Clinical results using biochemotherapy as a standard of care in advanced melanoma

J. Wolchok, P. Chapman, K. Panageas, 2002, Melanoma research.

The unfulfilled promise of melanoma vaccines.

P. Livingston, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Construction of Immunogenic GD3‐Conjugate Vaccines

H. Oettgen, P. Livingston, M. Calves, 1993, Annals of the New York Academy of Sciences.

Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3.

L. Old, H. Oettgen, R. Yu, 1990, Cancer research.

Cell-surface antigens of melanoma recognized by human monoclonal antibodies.

L. Old, H. Oettgen, K. Furukawa, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Ganglioside antigens expressed by human cancer cells.

G. Ritter, P. Livingston, Livingston Po, 1991, Seminars in cancer biology.

Antibody-dependent cell-mediated cytotoxicity for cultured autologous melanoma cells.

H. Oettgen, C. Pinsky, H. Shiku, 1981, Cellular immunology.

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.

P. Chapman, W. Hwu, S. Krown, 2004, Vaccine.

Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside

P. Chapman, W. Hwu, Dianna Y. Wu, 2004, Clinical Cancer Research.

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial

Larry Norton, C. Hudis, L. Norton, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

H. Scher, W. Bornmann, M. Fazzari, 1999, Proceedings of the National Academy of Sciences of the United States of America.

A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm

K. Lloyd, G. Ragupathi, P. Livingston, 1998, Glycoconjugate Journal.

Phase I I S tudy o f T emozolomide P lus T halidomide f or t he Treatment o f M etastatic M elanoma

J. Menell, J. Wolchok, A. Houghton, 2003 .

A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.

E. Gilboa, V. Reuter, N. Bander, 1992, Human gene therapy.

A high-throughput O-glycopeptide discovery platform for seromic profiling.

Thomas P. Clausen, H. Wandall, O. Blixt, 2010, Journal of proteome research.

Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.

M. Hollingsworth, J. Taylor‐Papadimitriou, H. Wandall, 2010, Cancer research.

Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate

M. Breimer, S. Danishefsky, K. Lloyd, 1998, Glycoconjugate Journal.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Fogh, M. Pollack, P. Livingston, 1981, Journal of the National Cancer Institute.

Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccine

Philip O. Livingston, Govind Ragupathi, Payal Damani, 2009, Cancer Immunology, Immunotherapy.

From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.

Qian Wan, Guangbin Yang, Ouathek Ouerfelli, 2009, Journal of the American Chemical Society.

Monocyte-mediated suppression of lymphocyte cytotoxic activity for cultured autologous melanoma cells.

S. Gupta, P. Livingston, R. Schulof, 1981, Cellular immunology.

Experimental and clinical studies with active specific immunotherapy.

P. Livingston, 1989, Progress in clinical and biological research.

Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma

J. Menell, J. Wolchok, A. Houghton, 2006 .

Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines.

H. Oettgen, B. Dupont, J. Fogh, 2008, Tissue antigens.

Vaccin a conjugue acide polysialique-klh

P. Livingston, G. Ragupathi, 2000 .

Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells

C. Musselli, G. Ragupathi, P. Livingston, 1999, Cancer Immunology and Immunotherapy.

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

J. Menell, J. Wolchok, A. Houghton, 2006, Cancer.

Synthetic and Immunological Studies on Clustered Modes of Mucin‐Related Tn and TF O‐Linked Antigens: The Preparation of a Glycopeptide‐Based Vaccine for Clinical Trials Against Prostate Cancer.

S. Kuduk, Xiao-tao Chen, S. Danishefsky, 1999 .

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.

A. Houghton, P. Chapman, Philip S. Livingston, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.

L. Old, A. Deleo, H. Oettgen, 1985, Journal of immunology.

Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis.

S. Walkley, P. Livingston, L. Goodman, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Clinical Trials with a Polyvalent Breast Cancer Vaccine.

P. Livingston, 1998 .

Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside

G. Ragupathi, P. Livingston, L. Williams, 2004, Clinical Cancer Research.

Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.

S. Danishefsky, G. Ragupathi, P. Livingston, 2009, Journal of the American Chemical Society.

Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.

M. Hollingsworth, J. Taylor‐Papadimitriou, H. Wandall, 2010, Cancer research.